Discussion of two important clinical trials demonstrating equivalent survival for sublobar resection versus lobectomy for clinical stage IA.
Date
Duration
1 hr. 2 min.
Experts provide insight on the management of patients born with Tetralogy of Fallot.
Date
Duration
1 hr. 32 min.

A panel of leaders in cardiothoracic surgery will explore the cost of patient safety relative to the effects on education, how public reporting of patient safety is often confusing to patients, and how expected patient safety results may lead to disproportionate investments and difficult prioritization decisions.

Topics will include: 

Date
Duration
1 hr. 2 min.

This webinar aims to help early career surgeons navigate their way through challenging procedures that do not yield the optimum outcome for the patient, support their OR team during these difficult experiences, and process the death of a patient.

This is the first event in a quarterly webinar series for early career surgeons. 


Moderators

Reilly D. Hobbs, MD, MBS
University of Utah/Primary Children's Medical Center
Salt Lake City, UT

Brian A. Mitzman, MD
University of Utah
Salt Lake City, UT

Date
Duration
1 hr.

In this episode of the STS Webinar Series, expert panelists present a global update on a potential new alternative approach to the surgical management of aortic valve disease: robotic aortic valve replacement (RAVR). Discussions will also focus on how aortic valve disease is managed with transcatheter or surgical aortic valve replacement.

Date
1 hr. 14 min.

STS is pleased to co-present this free webinar on the Advances in Surgery channel. Creation of a free account on the AIS site is required to view the program. 

Date

Watch STS President Thomas MacGillivray and DEI consultant James Pogue discuss diversity, equity, and inclusion. The video includes Q&A, insights from moderators, and an update on the Society’s efforts to bolster its commitment to DEI. Viewers will come away with a deeper understanding of DEI, and the opportunities and challenges in advancing a culture of inclusivity within STS and the specialty.

Moderators

Thomas E. MacGillivray, MD
STS President
Washington, DC

James Pogue, PhD
President and CEO, JP Enterprises
Dallas, Texas

Date
Duration
1 hr. 6 min.

Cardiothoracic surgeons and trainees who are underrepresented in medicine (URiM) will discuss challenges and successes they’ve experienced throughout their careers. Additionally, the panel will share what they have learned from these experiences and how to apply those lessons toward supporting other surgeons from underrepresented groups.

Date
1 hr. 1 min.

Diversity in the physician workforce is a key component of delivering the best care to our increasingly heterogeneous patient population. The experience of Asians in cardiothoracic surgery is not well known. With a paucity of published evidence, the webinar panel will introduce the topic through the lived experience of Asians in the specialty. The discussion will explore: 

Date
Duration
1 hr.

Aortic regurgitation is an undertreated condition, often because patients are not referred in a timely fashion for intervention. During this STS webinar, attendees will hear from an expert panel on the evidence base for timing of intervention as well as evolving treatment options. Conventional surgical aortic valve repair can be considered alongside the Ross procedure and transcatheter interventions with dedicated devices. Webinar participants will be better informed on how to treat this patient population.

Sponsored by JenaValve Technology, Inc. 

Date
Duration
1 hr. 3 min.

The management of stage IIIA non-small cell lung cancer (NSCLC) is evolving in the era of immune checkpoint inhibitor therapy. In the past, there has been a great deal of controversy regarding the optimal management of patients with N2 nodal metastasis at the time of diagnosis of NSCLC. There are some new questions to address when considering the results of the Checkmate 816 and the NADIM II clinical trials which demonstrated improved disease-free survival and overall survival with neoadjuvant combined chemotherapy and Nivolumab.

Date
Duration
58 min.

Recent approvals by the U.S. Food and Drug Administration (FDA) have made available two new technologies for treating aortic disease. The GORE® TAG® Thoracic Branch Endoprosthesis (TBE) is single-branch aortic stent graft that provides an off-the-shelf solution for patients that need zone II aortic coverage and obviates the need for prior left subclavian revascularization. The Thoraflex Hybrid Frozen Elephant Trunk (FET) device is a pre-mated surgical graft and an aortic stent graft to facilitate single-stage treatment of arch and proximal descending aortic pathologies.

Date
Duration
1 hr. 7 min.